These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33957843)

  • 1. Formulation Development and Improved Stability of a Combination Measles and Rubella Live-Viral Vaccine Dried for Use in the Nanopatch
    Wan Y; Gupta V; Bird C; Pullagurla SR; Fahey P; Forster A; Volkin DB; Joshi SB
    Hum Vaccin Immunother; 2021 Aug; 17(8):2501-2516. PubMed ID: 33957843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thermostability of Measles and Rubella Vaccines in a Microneedle Patch.
    Joyce JC; Collins ML; Rota PA; Prausnitz MR
    Adv Ther (Weinh); 2021 Oct; 4(10):. PubMed ID: 34926791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination.
    Prausnitz MR; Goodson JL; Rota PA; Orenstein WA
    Curr Opin Virol; 2020 Apr; 41():68-76. PubMed ID: 32622318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].
    Adigweme I; Akpalu E; Yisa M; Donkor S; Jarju LB; Danso B; Mendy A; Jeffries D; Njie A; Bruce A; Royals M; Goodson JL; Prausnitz MR; McAllister D; Rota PA; Henry S; Clarke E
    Trials; 2022 Sep; 23(1):775. PubMed ID: 36104719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the thermal stability of live-attenuated Rubella vaccine (Takahashi strain) formulated and lyophilized in different stabilizers.
    Shokri S; Shahkarami MK; Shafyi A; Mohammadi A; Esna-Ashari F; Hamta A
    J Virol Methods; 2019 Feb; 264():18-22. PubMed ID: 30144493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles vaccination using a microneedle patch.
    Edens C; Collins ML; Ayers J; Rota PA; Prausnitz MR
    Vaccine; 2013 Jul; 31(34):3403-9. PubMed ID: 23044406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with live rubella virus vaccine combined with live vaccines against measles and mumps.
    Smorodintsev AA; Nasibov MN; Jakovleva NV
    Bull World Health Organ; 1970; 42(2):283-9. PubMed ID: 5310140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Stabilizing Formulations of a Trivalent Inactivated Poliovirus Vaccine in a Dried State for Delivery in the Nanopatch™ Microprojection Array.
    Wan Y; Hickey JM; Bird C; Witham K; Fahey P; Forster A; Joshi SB; Volkin DB
    J Pharm Sci; 2018 Jun; 107(6):1540-1551. PubMed ID: 29421219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measles and rubella microarray array patches to increase vaccination coverage and achieve measles and rubella elimination in Africa.
    Richardson LC; Moss WJ
    Pan Afr Med J; 2020; 35(Suppl 1):3. PubMed ID: 32373254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries.
    Kumar P; Shukla RS; Patel A; Pullagurla SR; Bird C; Ogun O; Kumru OS; Hamidi A; Hoeksema F; Yallop C; Bines JE; Joshi SB; Volkin DB
    Hum Vaccin Immunother; 2021 Jul; 17(7):2298-2310. PubMed ID: 33861183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quality analysis of a combined domestic vaccine for the prevention of measles, rubella and mumps].
    Binyatova AS; Unasova TN; Iliasova TN; Sarkisyan KА; Fadeikina OV; Movsesyants AA
    Vopr Virusol; 2022 Nov; 67(5):414-422. PubMed ID: 36515287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.
    Goujon C; Gougeon ML; Tondeur L; Poirier B; Seffer V; Desprès P; Consigny PH; Vray M;
    Vaccine; 2017 Oct; 35(45):6166-6171. PubMed ID: 28958813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of nationwide supplementary immunization in Lao People's Democratic Republic: Population-based seroprevalence survey of anti-measles and anti-rubella IgG in children and adults, mathematical modelling and a stability testing of the vaccine.
    Hachiya M; Miyano S; Mori Y; Vynnycky E; Keungsaneth P; Vongphrachanh P; Xeuatvongsa A; Sisouk T; Som-Oulay V; Khamphaphongphane B; Sengkeopaseuth B; Pathammavong C; Phounphenghak K; Kitamura T; Takeda M; Komase K
    PLoS One; 2018; 13(3):e0194931. PubMed ID: 29596472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live vaccine preserved at room temperature: Preparation and characterization of a freeze-dried classical swine fever virus vaccine.
    Zuo XX; Zhao YH; Zhou MX; Deng BH; Hu LG; Lv F; Lu Y; Hou JB
    Vaccine; 2020 Dec; 38(52):8371-8378. PubMed ID: 33199076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients.
    Feldman AG; Beaty BL; Ferrolino JA; Maron G; Weidner HK; Ali SA; Bitterfeld L; Boulware MA; Campbell KM; Carr E; Chapman S; Chang YC; Cunningham R; Dallas RH; Dantuluri KL; Domenick BN; Ebel NH; Elisofon S; Fawaz R; Foca M; Gans HA; Gopalareddy VV; Gu C; Gupta NA; Harmann K; Hollenbeck J; Huppler AR; Jaramillo C; Kasi N; Kerkar N; Lerret S; Lobritto SJ; Lopez MJ; Marini E; Mavis A; Mehra S; Moats L; Mohandas S; Munoz FM; Mysore KR; Onsan C; Ovchinsky N; Perkins K; Postma S; Pratscher L; Rand EB; Rowe RK; Schultz D; Sear K; Sell ML; Sharma T; Stoll J; Vang M; Villarin D; Weaver C; Wood P; Woodford-Berry O; Yanni G; Danziger-Isakov LA
    JAMA Netw Open; 2023 Oct; 6(10):e2337602. PubMed ID: 37824141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.
    Li Y; Chu SY; Yue C; Wannemuehler K; Xie S; Zhang F; Wang Y; Zhang Y; Ma R; Li Y; Zuo Z; Rodewald L; Xiao Q; Feng Z; Wang H; An Z
    Lancet Infect Dis; 2019 Apr; 19(4):402-409. PubMed ID: 30833160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
    Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group
    Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.